Top

08-31-2018 | Flash glucose monitoring | Article

Use of flash glucose-sensing technology (FreeStyle Libre) in youth with type 1 diabetes: AWeSoMe study group real-life observational experience

Journal: Acta Diabetologica

Authors: Zohar Landau, Shirli Abiri, Noah Gruber, Yael Levy-Shraga, Avivit Brener, Yael Lebenthal, Galia Barash, Orit Pinhas-Hamiel, Mariana Rachmiel

Publisher: Springer Milan

Abstract

Aims

Frequent glucose testing is required for optimal management of type 1 diabetes (T1D). Limited data are available regarding real-world experience of the novel technology for monitoring by continuous interstitial fluid glucose (IFG), using flash glucose-sensing technology (FSL-CGM). We aimed to assess the effect of FSL-CGM in a real-life clinical setting on glycemic control parameters, compliance, and adverse events among pediatric and young adult T1D patients.

Methods

This observational multi-center study assessed FSL-CGM use (6–12 months) in T1D patients (mean ± SD age 13.4 ± 4.9 years) who purchased the device out-of-pocket. Outcome measures included HbA1c, mean IFG levels, CGM metrics [time in hypoglycemia (< 54 mg/dL; < 3 mmol/L), in target range (70–180 mg/dL; 3.9–10 mmol/L), and in hyperglycemia > 240 mg/dL; > 13.3 mmol/L)], frequency of self-monitoring of blood glucose, acute complications, skin reactions, and reasons for initiation/discontinuation.

Results

Among patients with regular use of the FSL-CGM (n = 59), mean HbA1c decreased from 8.86 ± 0.23 to 8.05 ± 0.2% (73.3–64.5 mmol/mol) in 3 months (p = 0.0001) and plateaued thereafter. A clinically significant reduction in HbA1c (defined as a decrease of ≥ 0.5%) was associated with shorter diabetes duration. Of 71 patients who initiated use of the FSL-CGM, 12 (16.9%) discontinued during the study period. No statistically significant changes were found after FSL-CGM use, in mean and standard deviation IFG levels, and in time of glucose levels in target, hypoglycemia, and hyperglycemia ranges. One patient with hypoglycemia unawareness was found dead-in-bed while using FSL-CGM.

Conclusions

Real-life observational data in a self-selected young T1D population demonstrated a significant and sustained reduction in HbA1c with FSL-CGM in one-third of the participants. Surveillance of glucose monitoring should be individualized, especially for patients with hypoglycemia unawareness.

Ziegler R, Heidtmann B, Hilgard D et al (2011) Frequency of SMBG correlates with HbA1c and acute complications in children and adolescents with type 1 diabetes. Pediatr Diabetes 12:11–17. https://doi.org/10.1111/j.1399-5448.2010.00650.x CrossRefPubMed

Miller KM, Beck RW, Bergenstal RM et al (2013) Evidence of a strong association between frequency of self-monitoring of blood glucose and hemoglobin A1c levels in T1D exchange clinic registry participants. Diabetes Care 36:2009–2014. https://doi.org/10.2337/dc12-1770 CrossRefPubMedPubMedCentral

Bergenstal RM, Tamborlane WV, Ahmann A et al (2010) Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med 363:311–320. https://doi.org/10.1056/NEJMoa1002853 CrossRefPubMed

Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Tamborlane WV, Beck RW et al (2008) Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 359:1464–1476. https://doi.org/10.1056/NEJMoa0805017 CrossRef

Charleer S, Mathieu C, Nobels F et al (2018) Effect of continuous glucose monitoring on glycemic control, acute admissions and quality of life: a real-world study. J Clin Endocrinol Metab. https://doi.org/10.1210/jc.2017-02498 CrossRefPubMed

Hermanides J, Nørgaard K, Bruttomesso D et al (2011) Sensor-augmented pump therapy lowers HbA1c in suboptimally controlled Type 1 diabetes; a randomized controlled trial. Diabet Med 28:1158–1167. https://doi.org/10.1111/j.1464-5491.2011.03256.x CrossRefPubMed

Weiss R, Garg SK, Bode BW et al (2015) Hypoglycemia reduction and changes in hemoglobin A1c in the ASPIRE in-home study. Diabetes Technol Ther 17:542–547. https://doi.org/10.1089/dia.2014.0306 CrossRefPubMedPubMedCentral

Battelino T, Nimri R, Dovc K et al (2017) Prevention of hypoglycemia with predictive low glucose insulin suspension in children with type 1 diabetes: a randomized controlled trial. Diabetes Care 40:764–770. https://doi.org/10.2337/dc16-2584 CrossRefPubMed

Wong JC, Foster NC, Maahs DM et al (2014) Real-time continuous glucose monitoring among participants in the T1D Exchange clinic registry. Diabetes Care 37:2702–2709. https://doi.org/10.2337/dc14-0303 CrossRefPubMedPubMedCentral

10.

Rachmiel M, Landau Z, Boaz M et al (2015) The use of continuous glucose monitoring systems in a pediatric population with type 1 diabetes mellitus in real-life settings: the AWeSoMe Study Group experience. Acta Diabetol 52:323–329. https://doi.org/10.1007/s00592-014-0643-6 CrossRefPubMed

11.

Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group (2010) Effectiveness of continuous glucose monitoring in a clinical care environment: evidence from the Juvenile Diabetes Research Foundation continuous glucose monitoring (JDRF-CGM) trial. Diabetes Care 33:17–22. https://doi.org/10.2337/dc09-1502 CrossRef

12.

Edge J, Acerini C, Campbell F et al (2017) An alternative sensor-based method for glucose monitoring in children and young people with diabetes. Arch Dis Child 102:543–549. https://doi.org/10.1136/archdischild-2016-311530 CrossRefPubMedPubMedCentral

13.

Bonora B, Maran A, Ciciliot S et al (2016) Head-to-head comparison between flash and continuous glucose monitoring systems in outpatients with type 1 diabetes. J Endocrinol Investig 39:1391–1399. https://doi.org/10.1007/s40618-016-0495-8 CrossRef

14.

Al Hayek AA, Robert AA, Al Dawish MA (2017) Evaluation of FreeStyle libre flash glucose monitoring system on glycemic control, health-related quality of life, and fear of hypoglycemia in patients with type 1 diabetes. Clin Med Insights Endocrinol Diabetes 10:1179551417746957. https://doi.org/10.1177/1179551417746957 CrossRefPubMedPubMedCentral

15.

Bolinder J, Antuna R, Geelhoed-Duijvestijn P et al (2016) Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet 388:2254–2263. https://doi.org/10.1016/S0140-6736(16)31535-5 CrossRefPubMed

16.

Dunn TC, Xu Y, Hayter G, Ajjan RA (2018) Real-world flash glucose monitoring patterns and associations between self-monitoring frequency and glycaemic measures: a European analysis of over 60 million glucose tests. Diabetes Res Clin Pract 137:37–46. https://doi.org/10.1016/j.diabres.2017.12.015 CrossRefPubMed

17.

Szadkowska A, Gawrecki A, Michalak A et al (2017) Flash glucose measurements in children with type 1 diabetes in real-life settings: to trust or not to trust? Diabetes Technol Ther. https://doi.org/10.1089/dia.2017.0287 CrossRefPubMed

18.

Massa GG, Gys I, Op ‘t Eyndt A et al (2018) Evaluation of the FreeStyle® libre flash glucose monitoring system in children and adolescents with type 1 diabetes. Horm Res Paediatr 89:189–199. https://doi.org/10.1159/000487361 CrossRefPubMed

19.

Dover AR, Stimson RH, Zammitt NN, Gibb FW (2017) Flash glucose monitoring improves outcomes in a type 1 diabetes clinic. J Diabetes Sci Technol 11:442–443. https://doi.org/10.1177/1932296816661560 CrossRefPubMedPubMedCentral

20.

McKnight JA, Gibb FW (2017) Flash glucose monitoring is associated with improved glycaemic control but use is largely limited to more affluent people in a UK diabetes centre. Diabet Med 34:732–732. https://doi.org/10.1111/dme.13315 CrossRefPubMed

21.

Ish-Shalom M, Wainstein J, Raz I, Mosenzon O (2016) Improvement in glucose control in difficult-to-control patients with diabetes using a novel flash glucose monitoring device. J Diabetes Sci Technol 10:1412–1413. https://doi.org/10.1177/1932296816653412 CrossRefPubMedPubMedCentral

22.

Haak T, Hanaire H, Ajjan R et al (2017) Use of flash glucose-sensing technology for 12 months as a replacement for blood glucose monitoring in insulin-treated type 2 diabetes. Diab Ther 8:573–586. https://doi.org/10.1007/s13300-017-0255-6 CrossRef

23.

Duca LM, Wang B, Rewers M, Rewers A (2017) Diabetic ketoacidosis at diagnosis of type 1 diabetes predicts poor long-term glycemic control. Diabetes Care 40:1249–1255. https://doi.org/10.2337/dc17-0558 CrossRefPubMed

24.

Reddy M, Jugnee N, El Laboudi A et al (2018) A randomized controlled pilot study of continuous glucose monitoring and flash glucose monitoring in people with type 1 diabetes and impaired awareness of hypoglycaemia. Diabet Med 35:483–490. https://doi.org/10.1111/dme.13561 CrossRefPubMed

25.

Bolinder J, Antuna R, Geelhoed-Duijvestijn P et al (2017) Cutaneous adverse events related to FreeStyle libre device—authors’ reply. Lancet 389:1396–1397. https://doi.org/10.1016/S0140-6736(17)30893-0 CrossRefPubMed

26.

Herman A, Aerts O, Baeck M et al (2017) Allergic contact dermatitis caused by isobornyl acrylate in Freestyle® Libre, a newly introduced glucose sensor. Contact Dermat 77:367–373. https://doi.org/10.1111/cod.12866 CrossRef

27.

Englert K, Ruedy K, Coffey J et al (2014) Skin and adhesive issues with continuous glucose monitors: a sticky situation. J Diabetes Sci Technol 8:745–751. https://doi.org/10.1177/1932296814529893 CrossRefPubMedPubMedCentral

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform.

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »